These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35758897)

  • 1. BRET-Based Self-Cleaving Biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery.
    Hou N; Peng C; Zhang L; Zhu Y; Hu Q
    Microbiol Spectr; 2022 Aug; 10(4):e0255921. PubMed ID: 35758897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
    Kilianski A; Mielech AM; Deng X; Baker SC
    J Virol; 2013 Nov; 87(21):11955-62. PubMed ID: 23986593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor.
    O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC
    Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
    Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
    Grum-Tokars V; Ratia K; Begaye A; Baker SC; Mesecar AD
    Virus Res; 2008 Apr; 133(1):63-73. PubMed ID: 17397958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
    Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
    Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.
    Zhu J; Zhang H; Lin Q; Lyu J; Lu L; Chen H; Zhang X; Zhang Y; Chen K
    Drug Des Devel Ther; 2022; 16():1067-1082. PubMed ID: 35450403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
    Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.
    Brown AS; Ackerley DF; Calcott MJ
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
    Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
    PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
    Rothan HA; Teoh TC
    Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
    Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
    Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
    Scholle MD; O'Kane PT; Dib S; Gurard-Levin ZA
    Antiviral Res; 2022 Apr; 200():105279. PubMed ID: 35278580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
    Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
    J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.